Vanguard Group Inc In8 Bio, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INAB
# of Institutions
27Shares Held
7.62MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD1.67MShares$535,8840.18% of portfolio
-
683 Capital Management, LLC New York, NY1.35MShares$432,0970.03% of portfolio
-
Sigma Planning Corp Ann Arbor, MI851KShares$272,4090.01% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT829KShares$265,3360.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL435KShares$139,1380.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $7.84M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...